Imago BioSciences

Please note: The information displayed on this page might be outdated.
Imago BioSciences: Operator of a biotechnology company intended to develop anti-cancer therapeutics for the treatment of genetic diseases. The company's therapeutics are developed for neoplastic diseases of the bone marrow for altering gene expression patterns by targeting enzymes that regulate gene transcription, enabling medical practitioners to improve the management of proliferative diseases of the bone marrow and modulation of the immune system.
Basic Materials
Based in...
US - Pacific
2729 Debbie Court
San Carlos, CA 94070
United States

Company Participants at Fall Private Company Showcase 2020

Ed Baracchini
Imago BioSciences, Chief Business Officer
Executive with over 25 years of experience in structuring and negotiating; research and development partnerships, mergers and acquisitions, and licensing agreements. Personally has negotiated more than 80 business transactions with multinational, European, and Asian pharmaceutical firms, biotechnology companies and leading universities, leading to transactions valued in excess of $5.3 billion. Significant experience in alliance management, strategic planning, IR/PR. Additionally, a key member of executive teams that have raised over $850 million in private and public financing, and have successfully completed multiple IPOs and mergers. Specialties: shaping corporate messages, opening doors by leveraging rolodex of >3000 industry executives/scientists, structuring strategic collaborations, negotiating agreements, managing and organizing due diligence, assessing markets and deal valuations, financial modeling
Hugh Rienhoff
Imago BioSciences, Chief Executive Officer
Dr. Rienhoff is a physician, entrepreneur and founder of several biotech and presently serves as CEO of Imago BioSciences. Dr. Rienhoff was the founder and CEO of FerroKin Biosciences, a development stage company that was acquired by Shire in for $325 million in 2012. He has more than 20 years experience as both a venture investor and entrepreneur in the life science sector. He was a partner at New Enterprise Associates and later, a director of Abingworth Management Ltd., running their US operation. Dr. Rienhoff is an Adjunct Scientist at the Children's Hospital Oakland Research Institute. He received his M.D. from the Johns Hopkins University School of Medicine and his B.A. from Williams College.